drugset / Trial / NCT05282940

Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product

NCT05282940

Phase 1 Completed 36 enrolled Laboratorios Andromaco S.A.
RandomizedCrossoverOpen-labelBasic science

Summary

This study will investigate the bioavailability in women of 2 tablet formulations containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The study will be performed at a single site with 36 subjects. Participants will take 2 tablets of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 14 days between each study period.

Timeline

Start
2022-02-26
Primary completion
2022-03-15
Completion
2022-04-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levonorgestrel Small molecule 15 mg
Comparator ethinyl estradiol Small molecule 0.03 mg

Indications

No indication recorded.